Date: August 13, 2026

Consolidated Financial Highlights

| Particulars | Q1FY27 | Q1FY26 | YoY Change |

| Revenue from Operations | ₹19.4 Cr | ₹17.8 Cr | 9.13% |

| EBITDA | ₹2.4 Cr | ₹5.2 Cr | -52.96% |

| EBITDA Margin % | 12.51% | 29.02% | -1651 bps |

| Profit After Tax (PAT)* | ₹1.8 Cr | ₹3.1 Cr | -42.27% |

| PAT Margin % | 9.17% | 17.33% | -816 bps |

*PAT represents Profit After Tax from continuing operations

Financial Performance Analysis

Revenue Growth Drivers:

  • Revenue growth of 9.13% YoY to ₹19.38 Cr from ₹17.76 Cr in Q1 FY26
  • Driven by higher patient volumes at mature hubs, sustained traction in advanced IVF protocols, and steady contribution from international patients

EBITDA Performance:

  • EBITDA declined 52.96% YoY to ₹2.42 Cr from ₹5.15 Cr
  • EBITDA margin contracted to 12.51% from 29.02%
  • Decline attributed to operating spends ahead of FY27 hub rollout including:
  • Preoperationalisation costs for South Extension hub
  • Preparatory expenses for Nagpur and Gurgaon hubs
  • Incremental clinical talent hiring
  • SiD/ERICA integration costs
  • Seasonally muted revenue absorption in Q1

Normalized EBITDA:

  • Excluding expansion-related one-off costs, EBITDA would have been approximately ₹5.35 crore
  • Normalized EBITDA margin would have been approximately 27.63%

Profit After Tax:

  • PAT declined 42.27% YoY to ₹1.8 Cr from ₹3.1 Cr
  • PAT margin contracted to 9.17% from 17.33%

Operational Highlights

Network Expansion:

  • Expanded network to 8 hubs and 28 spokes as of reporting date
  • Clinical pregnancy success rate of 62% on first IVF attempt

New Facility Launches:

  • Commenced commercial operations at new IVF Centre/Hub at South Extension Part-II, New Delhi
  • First milestone of planned 19-centre expansion
  • Features Gaudium Signature Lab with AI-powered embryology tools (SiD and ERICA)

Board Approvals:

  • Approved establishment of "Gaudium Women Hospital, Lucknow" in Uttar Pradesh
  • 30-year land lease with 15-year lock-in period
  • Estimated project cost of up to ₹15 crore
  • Marks company's entry into Uttar Pradesh

Management Commentary

Dr. Manika Khanna, Chairperson and Managing Director, highlighted:

  • Q1 FY27 represents first full quarter as a listed company
  • Revenue growth reflects resilience of mature hubs and steady patient flow for advanced fertility care
  • Profitability moderated due to strategic investments ahead of expansion
  • Investments include clinical talent, systems, and readiness for ten hubs planned in FY27
  • IVF Treatment remains anchor of business with clinical outcomes exceeding 62% success in first attempt
  • Early impact of AI-led embryology tools (SiD and ERICA) visible in consistency of embryo selection

Expansion Roadmap

  • 10 hubs planned in FY27: South Extension operational, remaining progressing on track
  • Includes one in Delhi-NCR and one at Nagpur
  • 8 new centres planned in FY28 and 1 in FY29
  • Focus on technology moat through wider deployment of AI-led embryology across network
  • Further investments in patient experience
  • Debt-light balance sheet post-IPO
  • Clearly funded expansion plan

Company Background

Gaudium IVF and Women Health Limited is a leading fertility and women's healthcare provider in India offering:

  • Advanced reproductive solutions including IVF, ICSI, IUI
  • Fertility preservation
  • Infertility treatments
  • Advanced genetic testing
  • High-risk pregnancy care
  • Minimally invasive gynecological procedures
  • Integrated pregnancy care and 24/7 patient services

Founded in 2009, with centers across Delhi, Mumbai, Bangalore, Patna, Ludhiana, and Srinagar